Daclatasvir combo gets Breakthrough status

Share this article:

Bristol-Myers Squibb landed a Breakthrough Therapy designation for its daclatasvir + asunaprevir combination to treat genotype 1b hep. C. The regulator granted the designation based on Phase-III clinical data involving the all-oral, two-drug regimen.

If the drug mix sounds familiar, it is: the FDA granted Breakthrough Therapy status in October 2013 to an all-oral combination of daclatasvir, asunaprevir and BMS-791325, which is being studied in non-cirrhotic, treatment-naïve and experienced patients, as well as cirrhotic, treatment naïve and experienced patients.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.